KEY EVENTS IN Q4 2023
Ascelia Pharma gets acceptance for publication of Orviglance® review article in Investigative Radiology- Conversion of series C shares into ordinary shares for delivery to participants in incentive program and subsequent change in number of shares and votes
- Extraordinary General Meeting held on
November 13, 2023 resolved on proposal to introduce an employee stock option program Ascelia Pharma starts image reading phase and re-confirms Phase 3 SPARKLE results byMay 2024
KEY EVENTS AFTER THE PERIOD
- Nomination Committee appointed for the Annual General Meeting 2024
- Orviglance review article is published in Investigative Radiology
Ascelia Pharma secures financing of up toSEK 35 million
FINANCIAL SUMMARY Q4 (Oct - Dec) 2023
- Operating result of
SEK -11.1M (SEK -52.2M ) - Earnings per share of
SEK -0.31 (SEK -1.53 ) - Cash flow from operations of
SEK -15.9M (SEK -28.7M ) - Liquid assets and marketable securities of
SEK 21.9M (SEK 149.6M )
FINANCIAL SUMMARY FULL YEAR (Jan - Dec) 2023
- Operating result of
SEK -110.9M (SEK -147.0M ) - Earnings per share of
SEK -3.24 (SEK -3.77 ) - Cash flow from operations of
SEK -126.8M (SEK -125.3M ) - Liquid assets and marketable securities of
SEK 21.9M (SEK 149.6M )
“In 2023, our focus was on SPARKLE, the pivotal Phase 3 study for our orphan magnetic resonance imaging (MRI) contrast agent for liver imaging, Orviglance®. We successfully completed patient enrollment in March. In early August, the discovery of high intra-reader variability in the study image scoring by independent radiologists prevented us from evaluating the efficacy data from SPARKLE. Therefore, a new evaluation of the images with new independent readers was required. With the aim of reaching headline results with available funding, we focused all resources on the re-evaluation and implemented cost-cutting initiatives, including a significant reduction of the organization. In September, we shared our plan to complete the re-evaluation and reach headline results from SPARKLE by
A presentation for analysts, investors and media will be held today 9 February at
https://ir.financialhearings.com/ascelia-pharma-q4-report-2023
To participate via teleconference, please register through the link below. After registration, you will be provided with phone numbers and a conference ID to access the conference.
https://conference.financialhearings.com/teleconference/?id=50047318
It will also be possible to access the audiocast afterwards at the same address or on the website of
© Modular Finance, source